Norbert Ifrah

23.3k total citations · 2 hit papers
231 papers, 11.4k citations indexed

About

Norbert Ifrah is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Norbert Ifrah has authored 231 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Hematology, 69 papers in Public Health, Environmental and Occupational Health and 53 papers in Genetics. Recurrent topics in Norbert Ifrah's work include Acute Myeloid Leukemia Research (92 papers), Acute Lymphoblastic Leukemia research (68 papers) and Chronic Myeloid Leukemia Treatments (44 papers). Norbert Ifrah is often cited by papers focused on Acute Myeloid Leukemia Research (92 papers), Acute Lymphoblastic Leukemia research (68 papers) and Chronic Myeloid Leukemia Treatments (44 papers). Norbert Ifrah collaborates with scholars based in France, United States and Switzerland. Norbert Ifrah's co-authors include Michel Attal, Thierry Façon, Philippe Casassus, Catherine Payen, Jean‐François Rossi, Hervé Maisonneuve, Jean Roy, Hervé Dombret, Nöel Milpied and François Dreyfus and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Norbert Ifrah

221 papers receiving 11.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

1996 2.0k citations Norbert Ifrah et al. profile →
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

2014 479 citations Jacques Delaunay, Hervé Dombret et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Norbert Ifrah	7.3k	3.9k	3.5k	2.8k	1.8k	231	11.4k
Marilyn L. Slovak	6.9k 0.9×	4.4k 1.1×	4.0k 1.1×	2.8k 1.0×	1.0k 0.6×	152	11.7k
Elisabeth Paietta	7.8k 1.1×	4.7k 1.2×	3.0k 0.9×	4.3k 1.5×	1.4k 0.8×	278	12.9k
Norbert Vey	7.1k 1.0×	3.7k 1.0×	2.4k 0.7×	2.3k 0.8×	1.9k 1.0×	402	10.6k
Nigel H. Russell	8.9k 1.2×	4.4k 1.1×	3.3k 0.9×	2.5k 0.9×	1.9k 1.1×	355	12.4k
Börje S. Andersson	9.6k 1.3×	2.1k 0.5×	3.7k 1.0×	2.8k 1.0×	3.1k 1.8×	326	13.4k
Meir Wetzler	5.0k 0.7×	3.0k 0.8×	2.1k 0.6×	1.9k 0.7×	1.1k 0.6×	245	8.6k
Sherry Pierce	10.5k 1.4×	4.9k 1.3×	3.1k 0.9×	4.2k 1.5×	1.1k 0.6×	428	14.8k
Tapan M. Kadia	9.8k 1.3×	5.4k 1.4×	2.7k 0.8×	3.0k 1.1×	1.1k 0.6×	778	13.2k
Daniel J. DeAngelo	9.0k 1.2×	6.2k 1.6×	4.3k 1.2×	4.3k 1.5×	1.9k 1.0×	444	16.3k
Oliver G. Ottmann	10.4k 1.4×	4.9k 1.3×	4.0k 1.1×	3.3k 1.1×	2.4k 1.4×	372	16.1k

Countries citing papers authored by Norbert Ifrah

Since Specialization

Citations

This map shows the geographic impact of Norbert Ifrah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Ifrah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Ifrah more than expected).

Fields of papers citing papers by Norbert Ifrah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Ifrah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Ifrah. The network helps show where Norbert Ifrah may publish in the future.

Co-authorship network of co-authors of Norbert Ifrah

This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Ifrah. A scholar is included among the top collaborators of Norbert Ifrah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Ifrah. Norbert Ifrah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orlanducci, Florence, Marie C. Béné, Amira Ben Amara, et al.. (2024). Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia. Blood Advances. 8(16). 4262–4275. 2 indexed citations

Duployez, Nicolas, Juliette Lambert, Maël Heiblig, et al.. (2023). Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML. Blood. 142(Supplement 1). 4322–4322.

Touzart, Aurore, Anand Mayakonda, Joschka Hey, et al.. (2021). Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Science Translational Medicine. 13(595). 23 indexed citations

Touzart, Aurore, Étienne Lengliné, Mohamed Belhocine, et al.. (2019). Epigenetic Silencing Affects l -Asparaginase Sensitivity and Predicts Outcome in T-ALL. Clinical Cancer Research. 25(8). 2483–2493. 28 indexed citations

Lefeuvre, D., Christine Le Bihan-Benjamin, Norbert Ifrah, et al.. (2019). Breast cancer screening: Impact on care pathways. Cancer Medicine. 8(8). 4070–4078. 9 indexed citations

Alcantara, Marion, Mathieu Simonin, Ludovic Lhermitte, et al.. (2019). Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. Blood Advances. 3(13). 1981–1988. 14 indexed citations

Poiré, Xavier, Myriam Labopin, Emmanuelle Polge, et al.. (2018). Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. American Journal of Hematology. 94(2). 231–239. 13 indexed citations

Poiré, Xavier, Myriam Labopin, Johan Maertens, et al.. (2016). Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European society of Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation. 51. 1 indexed citations

Foucher, Etienne, Laurence Preisser, Erwan Garo, et al.. (2014). Correction: IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ. PLoS ONE. 9(1). 1 indexed citations

10.

Chevallier, Patrice, Nelly Robillard, Aude Charbonnier, et al.. (2012). Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood. 119(11). 2474–2477. 11 indexed citations

11.

Kosmider, Olivier, Éric Delabesse, Véronique Mansat‐De Mas, et al.. (2011). TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica. 96(7). 1059–1063. 31 indexed citations

12.

Vergez, François, Alexa S. Green, Jérôme Tamburini, et al.. (2011). High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 96(12). 1792–1798. 147 indexed citations

13.

Pigneux, Arnaud, Jean‐Luc Harousseau, Francis Witz, et al.. (2010). Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS. Journal of Clinical Oncology. 28(18). 3028–3034. 26 indexed citations

14.

Chapuis, Nicolas, Jérôme Tamburini, Alexa S. Green, et al.. (2010). Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. Clinical Cancer Research. 16(22). 5424–5435. 128 indexed citations

15.

Chapuis, Nicolas, Sophie Park, Laurent Léotoing, et al.. (2010). IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood. 116(20). 4240–4250. 68 indexed citations

16.

Chapuis, Nicolas, Jérôme Tamburini, Pascale Cornillet‐Lefèbvre, et al.. (2009). Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 95(3). 415–423. 113 indexed citations

17.

Tamburini, Jérôme, Caroline Elie, Valérie Bardet, et al.. (2007). Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 110(3). 1025–1028. 112 indexed citations

18.

Yakoub‐Agha, Ibrahim, Mathieu Kuentz, Norbert Ifrah, et al.. (2006). Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen–Identical Siblings Versus Human Leukocyte Antigen–Allelic–Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy. Journal of Clinical Oncology. 24(36). 5695–5702. 189 indexed citations

19.

François, Sylvie, Éric Delabesse, Laurence Baranger, et al.. (1998). Deregulated expression of theTAL1 gene by t(1;5)(p32;q31) in patient with T-cell acute lymphoblastic leukemia. Genes Chromosomes and Cancer. 23(1). 36–43. 11 indexed citations

20.

Guyétant, Serge, et al.. (1996). Histopathology of Bone Marrow after Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukaemia. Pathology - Research and Practice. 192(8). 790–795. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact